miltefosine has been researched along with Disease Exacerbation in 5 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 5.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "Patients with liver cirrhosis of different aetiologies are at a risk to develop HCC." | 2.66 | Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. ( Aslanidis, C; Buechler, C, 2020) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.50 | Topical agents and dressings for fungating wounds. ( Adderley, UJ; Holt, IG, 2014) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.44 | Topical agents and dressings for fungating wounds. ( Adderley, U; Smith, R, 2007) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 1.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loreto, ES | 1 |
| Tondolo, JSM | 1 |
| de Jesus, FPK | 1 |
| Engelmann, AM | 1 |
| de Andrade, CM | 1 |
| Santurio, JM | 1 |
| Zanette, RA | 1 |
| Kommers, GD | 1 |
| Silva, TM | 1 |
| Alves, SH | 1 |
| Buechler, C | 1 |
| Aslanidis, C | 1 |
| Adderley, UJ | 1 |
| Holt, IG | 1 |
| Mukhopadhyay, D | 1 |
| Mukherjee, S | 1 |
| Ghosh, S | 1 |
| Roy, S | 1 |
| Saha, B | 1 |
| Das, NK | 1 |
| Chatterjee, M | 1 |
| Adderley, U | 1 |
| Smith, R | 1 |
3 reviews available for miltefosine and Disease Exacerbation
| Article | Year |
|---|---|
Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Prolif | 2020 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2014 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2007 |
2 other studies available for miltefosine and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Respon | 2020 |
A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Antimony Sodium Gluconate; Antiprotozoal A | 2016 |